Versartis Inc (NASDAQ:VSAR) insider Jay Shepard sold 14,446 shares of Versartis stock in a transaction dated Thursday, February 8th. The stock was sold at an average price of $1.80, for a total transaction of $26,002.80. Following the sale, the insider now owns 602,298 shares of the company’s stock, valued at $1,084,136.40. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.
Shares of Versartis Inc (VSAR) opened at $1.72 on Wednesday. The company has a market cap of $61.77, a PE ratio of -0.44 and a beta of 2.11. Versartis Inc has a twelve month low of $1.60 and a twelve month high of $24.00. The company has a current ratio of 1.52, a quick ratio of 1.52 and a debt-to-equity ratio of 0.11.
Several hedge funds and other institutional investors have recently modified their holdings of VSAR. Orbimed Advisors LLC purchased a new stake in Versartis in the third quarter valued at approximately $123,000. Tudor Investment Corp ET AL purchased a new stake in Versartis in the second quarter valued at approximately $218,000. Numeric Investors LLC purchased a new stake in Versartis in the second quarter valued at approximately $246,000. Voya Investment Management LLC grew its holdings in Versartis by 26.1% in the second quarter. Voya Investment Management LLC now owns 14,960 shares of the biopharmaceutical company’s stock valued at $261,000 after purchasing an additional 3,094 shares during the period. Finally, First Quadrant L P CA grew its holdings in Versartis by 1,253.8% in the third quarter. First Quadrant L P CA now owns 120,500 shares of the biopharmaceutical company’s stock valued at $295,000 after purchasing an additional 111,599 shares during the period. Institutional investors and hedge funds own 48.73% of the company’s stock.
COPYRIGHT VIOLATION NOTICE: This piece of content was first published by Sports Perspectives and is the property of of Sports Perspectives. If you are viewing this piece of content on another domain, it was copied illegally and reposted in violation of US & international copyright & trademark laws. The legal version of this piece of content can be viewed at https://sportsperspectives.com/2018/02/14/versartis-inc-vsar-insider-jay-shepard-sells-14446-shares.html.
Versartis Company Profile
Versartis, Inc is an endocrine-focused biopharmaceutical company. The Company is engaged in developing a long-acting form of recombinant human growth hormone, somavaratan (VRS-317), for growth hormone deficiency (GHD), an orphan disease. The Company’s first indication for somavaratan is pediatric GHD.
Receive News & Ratings for Versartis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Versartis and related companies with MarketBeat.com's FREE daily email newsletter.